Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
This study is currently recruiting participants.
Verified October 2013 by BioMed Valley Discoveries, Inc
Information provided by (Responsible Party):
BioMed Valley Discoveries, Inc
First received: April 13, 2010
Last updated: October 9, 2013
Last verified: October 2013
This protocol will examine the safety of intravenous administration of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C. novyi-NT administered intravenously in patients with treatment-refractory solid tumor malignancies.
Solid Tumor Malignancies
Biological: Clostridium novyi-NT spores
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase I Safety Study of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Primary Outcome Measures:
- Safety and tolerability of C. novyi-NT spore administration in patients with advanced solid tumor malignancies will be measured over a 7-day inpatient admission with routine labs and continuous adverse event assessments. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Anti-tumor activity of C. novyi-NT spores will be assessed with serial imaging studies such as CT scans and blood-based tumor markers. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- Pharmacokinetics of the C. novyi-NT spores will be measured in routine blood sampling over the course of the study. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- The host immune and inflammatory response to C. novyi-NT spores will be measured in routine blood sampling over the course of the study. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||December 2014 (Final data collection date for primary outcome measure)
Experimental: Clostridium novyi-NT spores
Biological: Clostridium novyi-NT spores
Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
- anaerobic bacteria
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Diagnosis of an advanced solid tumor malignancy
- History of prior treatment with at least one line of systemic anticancer therapy, when an approved systemic therapy is available, and no curative option is available for continued treatment.
- Measurable disease as defined by RECIST 1.1 criteria.
- At least 4 weeks has elapsed since the completion of major surgery and the patient is fully recovered from this surgery and any post-surgical complications.
- ECOG performance status of 2 or less.
- Patient is at least 18 years of age
- Patient is capable of giving informed consent.
- Patient of childbearing potential (defined by the clinical sites' standards) is using adequate birth control measures (e.g., barrier method with spermicide; intrauterine device; implantable or injectable hormonal contraceptives; surgical sterilization) for the duration of the study and will continue to use such precautions for 12 months after receiving treatment.
- Patient has no significant valvular disease (trace or mild valvular stenosis or regurgitation is allowed).
- Patient is able to stay within 45 minutes driving time of an emergency room for 28 days following discharge.
- The patient has a caregiver for 28 days after dosing.
- Positive pregnancy test
- Serum creatinine level > 1.5 x the upper limit of normal (ULN), chronic renal failure requiring hemodialysis or peritoneal dialysis.
- Patient has any of the following hematologic parameters: Platelet count equal to or less than 100,000/mm3, Hemoglobin less than 9.0 g/dL, or an ANC less than 1,000 /mm3.
- Oxygen saturation (Sp02) of less than 95% on room air.
- Mean arterial blood pressure of less than 70 mmHg.
- Glasgow Coma Score of less than 15.
- Treatment with an investigational drug within the past 30 days or 5 half-lives of that drug.
- Documented evidence of primary brain malignancy or brain metastases.
- Clinically significant ascites or clinical evidence or history of portosystemic hypertension or cirrhosis.
- Laboratory evidence of hepatic dysfunction indicated by any of the following: bilirubin > 1.5 x the upper limit of normal, AST or ALT above 2.5X the upper limit of normal, alkaline phosphatase above 2.5X the upper limit of normal or an INR greater than 1.3.
- Patient has a foreign body which in the opinion of the treating investigator could be difficult to manage in case of infection (e.g. prosthetic hip).
- Clinically significant pleural effusion.
- Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart.
- Need for ongoing treatment with an immunosuppressive agent.
- History of solid organ transplantation (with the exception of a corneal transplant > 3 months prior to screening).
- History of an ischemic insult in the previous 12 months (myocardial infarction, cerebral vascular accident, ischemic tissue from injury, transient ischemic attack, or clinically significant peripheral vascular disease).
- Patient has a history of venous stasis resulting in venous stasis ulcers or > 2+ edema.
History of a significant medical illness deemed by the principal investigator or local investigators as unsuitable for the trial - for example:
i. Symptomatic congestive heart failure; ii. Psychiatric Illness/Social Situation that may make study dangerous; and iii. Unstable angina pectoris.
- Antibiotic allergies which would preclude treatment for a C. novyi-NT infection, in the event that antibiotics are required.
- Treatment with antibiotics within 2 weeks (14 days) of dosing.
- Active and clinically significant systemic or localized infection.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01118819
|Washington University School of Medicine
|St. Louis, Missouri, United States, 63110 |
|Contact: Lauren Trull 314-747-1864 firstname.lastname@example.org |
|Contact: Tonie Covelli 314-747-5543 email@example.com |
|Principal Investigator: Andrea Wang-Gillam, MD, PhD |
|Montefiore Medical Center
|Bronx, New York, United States, 10461 |
|Contact: Sanjay Goel, MD 718-904-2488 firstname.lastname@example.org |
|Contact: Mohammad Ghalib 718-405-8515 email@example.com |
|Principal Investigator: Sanjay Goel, MD |
BioMed Valley Discoveries, Inc
No publications provided
||BioMed Valley Discoveries, Inc
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 13, 2010
||October 9, 2013
||United States: Food and Drug Administration
Keywords provided by BioMed Valley Discoveries, Inc:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 05, 2014